Tesofensine
A triple monoamine reuptake inhibitor (serotonin, noradrenaline, dopamine) that produced up to 10.6% weight loss in Phase 2 trials — roughly double the efficacy of older appetite suppressants. Approved in Mexico; not yet FDA-approved.
What is Tesofensine?
Tesofensine is an oral small-molecule triple monoamine reuptake inhibitor that blocks the reuptake of serotonin, noradrenaline, and dopamine — the three neurotransmitters most involved in appetite, satiety, and reward. Originally developed by NeuroSearch for Alzheimer's and Parkinson's disease, weight loss was observed as a "side effect" in those trials, redirecting development toward obesity. In a Phase 2 trial published in The Lancet (203 patients, 24 weeks), tesofensine 0.5 mg produced 9.2% body weight loss — roughly double what sibutramine or rimonabant achieved. It is not a peptide, but is widely discussed alongside peptides in the weight loss and compounding pharmacy space. Tesofensine received regulatory approval in Mexico in 2023 and has FDA orphan drug designation for hypothalamic obesity and Prader-Willi syndrome (as Tesomet, combined with metoprolol).
What Tesofensine Is Investigated For
Tesofensine is investigated primarily for general obesity, hypothalamic obesity, and Prader-Willi syndrome hyperphagia, and the strongest evidence is the Phase 2 TIPO-1 trial published in The Lancet (203 patients, 24 weeks) showing dose-dependent weight loss up to 10.6% at 1 mg and 9.2% at the more tolerable 0.5 mg dose — roughly double what sibutramine or rimonabant produced. It received regulatory approval in Mexico in 2023 (marketed as Tesomet with a metoprolol beta-blocker to offset the cardiovascular signal) and has FDA orphan drug designation for hypothalamic obesity and Prader-Willi syndrome. The honest caveats are substantial. Tesofensine is not a peptide but a small-molecule triple monoamine reuptake inhibitor, it is not FDA-approved for any indication, and the Mexican Phase 3 data have not been fully published in peer-reviewed form — leaving long-term cardiovascular and psychiatric safety in larger populations inadequately characterized. The dose-dependent heart rate increase (~7.4 bpm at 0.5 mg) is a meaningful concern, serotonergic drug interactions (SSRIs, SNRIs, MAOIs, triptans) carry serotonin syndrome risk, and the regulatory basis for US compounding of an unapproved drug substance is contested.
History & Discovery
Tesofensine (NS2330) was discovered at NeuroSearch, a Danish CNS-focused biotech, as a triple monoamine reuptake inhibitor — blocking presynaptic transporters for serotonin, noradrenaline, and dopamine. The original development thesis was neurodegenerative: NeuroSearch tested tesofensine in Phase 2 trials for Alzheimer's disease and Parkinson's disease in the early 2000s, where it failed to demonstrate cognitive or motor benefit. What investigators noticed in those trials, however, was unexpected weight loss — substantial enough to redirect the molecule's development entirely toward obesity. The pivotal Phase 2 obesity study (TIPO-1) was published in The Lancet in 2008, with 203 patients across five Danish centers showing dose-dependent weight loss up to 10.6% at the 1 mg dose over 24 weeks, and 9.2% at the more tolerable 0.5 mg dose. Saniona, a Scandinavian biotech that acquired and continued the program, partnered with Mexican firm Medix, which completed Phase 3 in Mexico and obtained Mexican regulatory approval (as Tesomet) in 2023. Tesomet pairs tesofensine with metoprolol, a beta-blocker, to offset the dose-dependent heart rate increase observed with tesofensine alone. The molecule has FDA orphan drug designation for hypothalamic obesity and Prader-Willi syndrome but is not approved in the US for any indication. Note that tesofensine is a small molecule, not a peptide — it is included on this site because it is widely discussed alongside peptides in the obesity and compounding-pharmacy space.
How It Works
Tesofensine blocks the recycling of three brain chemicals — serotonin, noradrenaline, and dopamine — that control appetite, mood, and reward. By keeping more of these neurotransmitters active in the brain, it reduces hunger, increases the feeling of fullness, and decreases the reward drive to eat. It also slightly increases energy expenditure. Recent research shows it specifically silences hunger-promoting neurons in the hypothalamus.
Tesofensine is a triple monoamine reuptake inhibitor that blocks the presynaptic transporters for serotonin (SERT), noradrenaline (NET), and dopamine (DAT), increasing synaptic concentrations of all three neurotransmitters. The primary weight loss mechanism is appetite suppression (reduced food intake), with a minor contribution from increased energy expenditure. A 2024 study revealed that tesofensine silences GABAergic neurons in the lateral hypothalamus — a brain region directly involved in feeding behavior — providing a specific neuroanatomical target for its anorectic effects. The triple reuptake profile distinguishes it from SSRIs/SNRIs (which affect only 1-2 monoamines) and from GLP-1 agonists (which work through peripheral gut hormone signaling). In Phase 2 (203 patients, 24 weeks, Lancet), dose-dependent weight loss was observed: 4.5% (0.25 mg), 9.2% (0.5 mg), and 10.6% (1.0 mg) vs 2.0% placebo, with 0.5 mg considered the optimal therapeutic dose balancing efficacy and cardiovascular safety.
Evidence Snapshot
Human Clinical Evidence
Moderate. Phase 2 RCT published in The Lancet (203 patients, 24 weeks, 5 Danish centers): dose-dependent weight loss up to 10.6%, with 0.5 mg producing 9.2% loss (double sibutramine). Phase 3 completed in Mexico by Saniona's partner Medix, leading to regulatory approval. Tesomet (tesofensine + metoprolol) tested in hypothalamic obesity RCT showing significant weight loss with improved cardiovascular safety profile. FDA orphan drug designation for hypothalamic obesity and Prader-Willi syndrome.
Animal / Preclinical
Strong. Diet-induced obese rat models showed sustained weight loss superior to sibutramine and rimonabant. A 2024 study identified the specific neuronal mechanism: silencing of GABAergic lateral hypothalamic neurons (PMID: 38656972). Preclinical work supports both appetite suppression and modest energy expenditure increase.
Mechanistic Rationale
Strong. Triple monoamine reuptake inhibition for appetite control is pharmacologically well-established. The lateral hypothalamic GABAergic neuron silencing provides a specific mechanistic basis. The dopaminergic component distinguishes tesofensine from earlier serotonin-only approaches and may address reward-driven eating.
Research Gaps & Open Questions
What the current literature has not yet settled about Tesofensine:
- 01Long-term cardiovascular safety beyond 24 weeks at scale — TIPO-1 was a 24-week study, and the Mexican Phase 3 data have not been fully published in peer-reviewed form, leaving multi-year cardiovascular outcomes incompletely characterized.
- 02Psychiatric safety in larger and more diverse populations — monoamine reuptake inhibition carries rare but serious psychiatric risks, and the published data are inadequate to estimate event rates with confidence.
- 03Whether combination with GLP-1 agonists is safe and effective — mechanistically additive (central dopamine plus peripheral incretin signaling) but untested in dedicated trials.
- 04Direct head-to-head comparisons with semaglutide, tirzepatide, naltrexone-bupropion, and phentermine-topiramate.
- 05Hypothalamic obesity and Prader-Willi syndrome — orphan-designated indications where tesofensine's dopaminergic mechanism may be uniquely useful, but Phase 3 data in these populations are still emerging.
- 06Pediatric and adolescent use — entirely uncharacterized.
Forms & Administration
Tesofensine is taken as a once-daily oral tablet, typically 0.5 mg. The 0.25 mg dose is effective but less potent; the 1.0 mg dose produces more weight loss but more side effects. Tesomet combines tesofensine with metoprolol to manage heart rate effects. Available through some US compounding pharmacies with a prescription, and approved in Mexico for obesity.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Per the Mexican label and Phase 2/3 data, the therapeutic dose is 0.5 mg orally once daily. The 1.0 mg dose produces greater weight loss (~10.6% vs ~9.2%) but more side effects and cardiovascular signal; 0.25 mg is effective but less potent. For Tesomet (tesofensine + metoprolol), the dosing is similar with metoprolol added to manage the heart-rate effect.
Frequency
Once daily by mouth, typically in the morning to minimize sleep disruption from the noradrenergic and dopaminergic activity.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Tesofensine is intended for chronic, indefinite use in obesity, the same chronic-disease paradigm applied to GLP-1 agonists. There is no concept of cycling; published data have not characterized post-discontinuation rebound formally, but expectation is consistent with other appetite-suppressing pharmacotherapy.
Protocol Notes
Outside Mexico, tesofensine has no approved prescribing channel. Some US compounding pharmacies offer tesofensine, but the regulatory basis is contested: traditional 503A compounding requires either an FDA-approved drug substance or one on the FDA bulk-drug substances list, and tesofensine is neither. Material sold by research-chemical suppliers is not authorized for human use and quality cannot be verified. Cardiovascular monitoring (resting heart rate, blood pressure) is appropriate given the documented dose-dependent ~7.4 bpm heart rate increase at 0.5 mg. Patients on serotonergic medications (SSRIs, SNRIs, MAOIs, triptans) should not initiate tesofensine without evaluating serotonin syndrome risk.
Tesofensine is not FDA-approved. The doses cited reflect Mexican prescribing and the Phase 2/3 trial protocols, not US prescribing guidance. Use outside the Mexican-approved context is unsupervised and unregulated.
Timeline of Effects
Onset
Appetite suppression is typically reported within the first days of dosing, consistent with the rapid pharmacology of monoamine reuptake inhibition (no titration ramp is required as with GLP-1s). Measurable weight loss emerges within the first 2–4 weeks.
Peak Effect
In the Phase 2 TIPO-1 trial (24 weeks), the weight-loss curves had not fully plateaued at trial end at the 0.5 mg and 1.0 mg doses, suggesting peak effect extends beyond 6 months. Mexican Phase 3 data have not been fully published in peer-reviewed form, leaving long-duration kinetics incompletely characterized.
After Discontinuation
Tesofensine has a plasma half-life of approximately 9 days, so washout is gradual and the appetite-suppressing effect persists for several days after the last dose before fully resolving. Weight regain after discontinuation has not been formally characterized in the published data, but as with other appetite-suppressing pharmacotherapy, substantial regain within 6–12 months should be anticipated when chronic therapy is stopped.
Common Questions
Who Tesofensine Is NOT For
- •Concurrent use of monoamine oxidase inhibitors (MAOIs) — risk of hypertensive crisis and serotonin syndrome from combined monoaminergic effects.
- •Concurrent use of other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, MDMA) without careful clinical evaluation — additive serotonergic activity raises serotonin syndrome risk.
- •Uncontrolled hypertension or significant cardiovascular disease — the documented dose-dependent heart rate increase (~7.4 bpm at 0.5 mg) is a meaningful concern in patients with arrhythmias, ischemic heart disease, or poorly controlled blood pressure.
- •History of serious psychiatric illness including bipolar disorder, psychosis, or active suicidal ideation — monoamine reuptake inhibition can precipitate or worsen psychiatric symptoms in susceptible individuals.
- •Pregnancy — no human pregnancy safety data; the CNS-active pharmacology and absence of teratogenicity data warrant avoidance.
- •Breastfeeding — no human lactation data.
- •History of substance use disorder, particularly involving stimulants — the dopaminergic activity carries theoretical reinforcement potential.
- •Pheochromocytoma — catecholaminergic activity is contraindicated.
Drug & Supplement Interactions
The most clinically important interaction domain is serotonergic: tesofensine combined with SSRIs, SNRIs, MAOIs, triptans, tramadol, MDMA, or other serotonergic agents raises serotonin syndrome risk through additive serotonergic load. MAOIs in particular are an absolute contraindication in either direction (start MAOI, must wait 14 days before tesofensine; start tesofensine, must wait roughly 5 half-lives, or about 6 weeks, before MAOI). The dopaminergic activity introduces theoretical interactions with antipsychotics (which block dopamine receptors and could be antagonized) and with dopamine-replacement therapy in Parkinson's disease (additive dopaminergic load). The noradrenergic activity adds to the cardiovascular effects of stimulants, decongestants (pseudoephedrine), and certain ADHD medications. The Tesomet combination with metoprolol is itself a designed pharmacokinetic and pharmacodynamic strategy to manage the cardiovascular effect of tesofensine. CYP-mediated metabolism interactions have been less extensively characterized than for the broader stimulant class, and clinicians prescribing tesofensine in Mexico should evaluate concurrent medications case by case.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved in the US
- • Heart rate increase is dose-dependent — cardiovascular monitoring recommended
- • Monoamine reuptake inhibition carries psychiatric risk (anxiety, mood changes) in susceptible individuals
- • Tesomet combination (with metoprolol) has better cardiovascular safety profile than tesofensine alone
- • May interact with SSRIs, SNRIs, MAOIs, and other serotonergic drugs — serotonin syndrome risk
What We Don't Know
Long-term cardiovascular safety beyond 24 weeks is not established in the published Phase 2 data. Psychiatric adverse event rates in larger populations are unclear — Phase 3 data from the Mexico program has not been fully published. Whether combining tesofensine with GLP-1 agonists is safe and effective is untested.
Legal Status
United States
Tesofensine is not FDA-approved for any indication. It has FDA orphan drug designation for hypothalamic obesity and Prader-Willi syndrome (as Tesomet, the metoprolol combination), but orphan designation is not approval. Some compounding pharmacies offer tesofensine, but the regulatory basis for compounding an unapproved drug substance is contested under FDA 503A rules. Research-chemical sources are not authorized for human use.
International
Approved in Mexico (2023) for obesity treatment, primarily through the Saniona-Medix partnership. Not approved by the EMA, UK MHRA, Health Canada, Australia's TGA, or any other major Western regulator. No public timeline exists for additional approvals.
Sports & Competition
Tesofensine is not currently listed by name on the WADA Prohibited List, but its monoamine reuptake inhibitor pharmacology overlaps with several stimulant categories (S6) prohibited in competition. Athletes subject to WADA, USADA, or equivalent codes should treat tesofensine as a high-risk substance and consult their governing body before use; the dopaminergic and noradrenergic activity is the kind of pharmacology anti-doping authorities scrutinize closely.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Tesofensine is a peptide, like semaglutide.
Reality
Tesofensine is a small-molecule oral drug, not a peptide. It is included on this site because it is widely discussed alongside peptides in obesity and compounding-pharmacy contexts, but the molecule, mechanism, and pharmacology are entirely distinct from the peptide hormone analog class.
Myth
Tesofensine is FDA-approved for weight loss.
Reality
Tesofensine is not FDA-approved for any indication. It has orphan drug designation for hypothalamic obesity and Prader-Willi syndrome (as Tesomet), but designation is not approval. Approval exists only in Mexico.
Myth
Tesofensine produces no cardiovascular effects, so it is safer than older stimulant appetite suppressants.
Reality
Tesofensine produces a dose-dependent heart rate increase of approximately 7.4 bpm at the 0.5 mg therapeutic dose. This is precisely why the Tesomet combination pairs it with metoprolol (a beta-blocker) — to manage the cardiovascular signal. Patients with cardiovascular disease, arrhythmia history, or uncontrolled hypertension face real risk and should not initiate tesofensine without careful evaluation.
Myth
Because tesofensine increases dopamine, it is essentially the same as Adderall or other stimulants.
Reality
Tesofensine inhibits dopamine reuptake at the dopamine transporter, which does increase synaptic dopamine, but its profile differs from amphetamines (which both block reuptake and reverse the transporter to actively release dopamine). The reinforcing potential is consequently lower than amphetamines, but it is non-zero, and patients with substance use disorder histories warrant caution.
Myth
Compounded tesofensine from US pharmacies is the same as the Mexican-approved Tesomet.
Reality
Tesomet is a specific formulation of tesofensine plus metoprolol manufactured under regulated conditions. US-compounded tesofensine is typically tesofensine alone, lacks the metoprolol cardioprotective component, and is sourced under a contested regulatory framework. Quality, potency, and cardiovascular safety profile differ and cannot be assumed to match the approved Mexican product.
Published Research
6 studiesTesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons.
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.
Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects.
Tesofensine induces appetite suppression and weight loss.
Tesofensine--a novel potent weight loss medicine.
Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.
203 patients, 24 weeks, up to 10.6% weight loss
Quick Facts
- Class
- Monoamine Reuptake Inhibitor
- Tier
- B
- Evidence
- Moderate
- Safety
- Limited Data
- Updated
- Apr 2026
- Citations
- 6PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.